Cassava Sciences (NASDAQ:SAVA - Get Free Report) is set to issue its quarterly earnings data before the market opens on Thursday, November 7th. Analysts expect the company to announce earnings of ($1.37) per share for the quarter. Persons that wish to register for the company's earnings conference call can do so using this link.
Cassava Sciences (NASDAQ:SAVA - Get Free Report) last posted its earnings results on Thursday, August 8th. The company reported $0.13 earnings per share for the quarter, topping analysts' consensus estimates of ($0.44) by $0.57. During the same quarter in the prior year, the business earned ($0.63) EPS. On average, analysts expect Cassava Sciences to post $-6 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
Cassava Sciences Stock Up 1.6 %
Shares of SAVA stock traded up $0.41 during trading hours on Friday, hitting $26.21. 1,382,005 shares of the company's stock traded hands, compared to its average volume of 1,709,887. The stock has a market cap of $1.26 billion, a PE ratio of -18.59 and a beta of -0.63. The stock's 50 day simple moving average is $27.99 and its 200 day simple moving average is $22.83. Cassava Sciences has a 12 month low of $8.79 and a 12 month high of $42.20.
Analyst Upgrades and Downgrades
Several research analysts have commented on SAVA shares. Rodman & Renshaw reaffirmed a "buy" rating and set a $107.00 target price on shares of Cassava Sciences in a report on Thursday, August 8th. HC Wainwright upgraded Cassava Sciences from a "neutral" rating to a "buy" rating and set a $116.00 price objective for the company in a research report on Tuesday, October 8th.
Check Out Our Latest Stock Analysis on Cassava Sciences
Cassava Sciences Company Profile
(
Get Free Report)
Cassava Sciences, Inc, a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease.
Featured Articles
Before you consider Cassava Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cassava Sciences wasn't on the list.
While Cassava Sciences currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
